Lilly's next-gen obesity drug shows reduction in blood sugar levels in trial [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
on ?Thursday, as it looks to widen its lead in the heavily ?contested market for GLP-1 drugs. Drug developers are racing to enter the highly competitive and booming obesity ?market dominated by injectable drugs such as Novo Nordisk's Wegovy and Lilly's Zepbound, prompting heavy investment in next-generation treatments that could deliver faster, deeper, or more durable weight loss. Lilly tested the drug, retatrutide, in patients with type 2 diabetes who had inadequate ?glycemic control with diet ?and exercise alone, and a mean duration of diabetes of two and a half years. During the 40-week trial, retatrutide reduced A1C, ?a measure of blood sugar over time, by an average of 1.7% to 2.0% across doses compared to an average reduction of 0.8% in placebo. For a key secondary ?goal, ?patients who took the drug lost up ?to an average of 16.8% of ?their weight. Overall, side effects were in line with those typically seen in weight-loss treatment trials, the company said, including
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- The Daily Chase: Energy prices surge as strikes on gulf facilities escalate [BNN Bloomberg (Canada)]BNN Bloomberg
- Novo Nordisk Targets Japan Self-Pay Market as Only 14,000 Access Obesity Drugs [Yahoo! Finance]Yahoo! Finance
- 1 Reason I'm Never Selling Novo Nordisk Stock [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India [Yahoo! Finance]Yahoo! Finance
- Ozempic Is About to Go Generic in India, China and Canada [The New York Times]The New York Times
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website